research LB1667 Successful treatment of rare linear lichen planopilaris with ixekizumab
Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
Search
for
Sort by
Research
30-60 / 1000+ results research Linear lichen planus distributed in the lines of Blaschko developing during intramuscular triamcinolone acetonide therapy for alopecia areata multiplex
Triamcinolone acetonide therapy for hair loss may cause a skin condition called linear lichen planus.
research Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
research Restolin - Successful Hair Loss Treatment!
research Efficacy of luliconazole combination shampoo in patients with seborrheic dermatitis
The luliconazole shampoo effectively reduces symptoms of seborrheic dermatitis and is well-tolerated.
research 1400 Low-intensity ultrasound protects human scalp hair follicles from taxane-induced toxicity
Low-intensity ultrasound may protect hair follicles from damage caused by a common chemotherapy drug.
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research Minoxidil
research Minoxidil
research Minoxidil
research Minoxidil
research Minoxidil
research Minoxidil
research Minoxidil
research Minoxidil
research Minoxidil
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Lentiviral Vector-Mediated Gene Transfer to Human Hair Follicles
research Linear lupus panniculitis of scalp: a case report from north-east India
A child with a rare scalp condition regrew hair after treatment.
research effects Of Low-level Laser Therapy (lllt) On Dermal Papilla Cell Proliferation And Insulin-like Growth Factor-1 (igf-1) Secretion From Balding Hair Follicles : #lb12
research Therapeutic Intervention in Lichen Planus Pilar (LPP): Synergy of Low-Level Laser Therapy and Topical Corticosteroid
Combining low-level laser therapy with topical corticosteroids effectively improved Lichen Planopilaris symptoms.
research Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
Lulican™ shampoo is more effective and better tolerated than Ketoconazole for treating scalp seborrheic dermatitis.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research Sarolaner, a novel parasiticide in the treatment of generalized demodicosis in dogs-a case study
Sarolaner effectively treats generalized demodicosis in dogs without side effects.
research 1409 Temporary cell cycle arrest by ALRN-6924: A novel, p53-targeting strategy to protect human scalp hair follicles against cyclophosphamide-induced alopecia
ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.